This comprehensive review has piqued the growing interest in pharmaceutical research towards leveraging natural products as multi-target modulators of both GLP-1 signaling and the TXNIP–thioredoxin system for the comprehensive treatment of MetS and its associated conditions. This evidence concerns the gene TXN and metabolic syndrome.